Drugs / rATG
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03342638 Background | Nov 2017 → Jul 2019 | relapsing-remitting multiple sclerosis | Northwestern University | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rATG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03342638 ↗ |
| Modality | Protein / enzyme biologic | “contains antibodies specific to the antigens commonly found on the surface of T cells” NCT03342638 ↗ |